NASDAQ$COLL
Collegium Pharmaceutical Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Collegium reported a net loss due to a $38.3 million product revenue adjustment related to returns adjustments, despite efforts to manage costs.
Collegium Pharmaceutical reported a net loss for Q4 2021, primarily due to a significant revenue adjustment related to product returns. While the company managed to contain operating expenses, the revenue adjustment significantly impacted the financial results. The company is focused on renegotiating Xtampza ER contracts and diversifying the business through acquisitions, with the BDSI acquisition expected to be transformative.
- Total net product revenues decreased to $27.4 million, including a $38.3 million product revenue adjustment.
- Xtampza ER net product revenues were $5.3 million, including returns adjustments of $13.8 million.
- Nucynta franchise net product revenues were $22.1 million, including returns adjustments of $24.5 million.
- Net loss for the quarter was ($25.0) million, or ($0.73) loss per share.
Headline financials
Revenue & EPS history
Collegium · Revenue · Quarterly
$27.4M
Revenue by segment
Collegium · $27.4M total across 2 segments · Q4 2021
- Nucynta Franchise$22.1M—80.7%
- Xtampza ER$5.3M—19.3%
Forward guidance
Collegium expects total revenues in the range of $315 million to $330 million for 2022. A more detailed outlook will be provided after the closing of the acquisition of BioDelivery Sciences International, Inc. (BDSI), expected late in the first quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+2.6%
Avg return
Earnings day
+4.9%
Avg return
5 days after
+2.2%
Avg return
30 days after
61%
28 / 46 earnings
Positive
+31.2%
Q3 2019
Best reaction
-17.6%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.7% | -2.2% | -8.9% | |
| Q4 2025 | -3.5% | -12.6% | -29.1% | |
| Q3 2025 | +4.4% | +16.5% | +17.8% | |
| Q1 2025 | +5.9% | +6.6% | +10.7% | |
| Q4 2024 | +2.2% | +0.2% | +4.5% | |
| Q3 2024 | -6.8% | -9.0% | -13.1% | |
| Q2 2024 | +2.5% | +5.9% | +7.3% | |
| Q1 2024 | -17.2% | -12.5% | -12.8% | |
| Q4 2023 | +14.5% | +15.8% | +25.1% | |
| Q3 2023 | +4.6% | +10.8% | +23.0% | |
| Q2 2023 | +6.8% | +9.5% | +7.9% | |
| Q1 2023 | +3.6% | +6.4% | -2.2% | |
| Q4 2022 | +1.7% | +0.5% | -10.0% | |
| Q3 2022 | +6.9% | +11.9% | +30.6% | |
| Q2 2022 | +11.4% | +7.2% | -1.0% | |
| Q1 2022 | +1.7% | +10.0% | +15.9% | |
| Q4 2021 | -14.0% | -17.7% | -14.1% | |
| Q3 2021 | -5.3% | +1.0% | -12.5% | |
| Q2 2021 | -17.6% | -23.7% | -19.2% | |
| Q1 2021 | +3.6% | -0.3% | -1.8% | |
| Q4 2020 | -9.6% | -14.1% | -8.8% | |
| Q3 2020 | +2.2% | +4.3% | +1.9% | |
| Q2 2020 | +6.6% | +13.4% | +16.4% | |
| Q1 2020 | +9.4% | +16.2% | +0.3% | |
| Q4 2019 | +5.2% | -1.5% | -27.4% | |
| Q3 2019 | +31.2% | +38.5% | +53.5% | |
| Q2 2019 | +4.0% | +9.6% | +0.9% | |
| Q1 2019 | +5.6% | -2.9% | -18.0% | |
| Q4 2018 | +18.5% | +22.4% | +2.0% | |
| Q3 2018 | -0.4% | +10.8% | +23.1% | |
| Q2 2018 | -5.7% | -2.0% | -15.7% | |
| Q1 2018 | +11.6% | +8.6% | +9.7% | |
| Q4 2017 | +17.9% | +6.3% | -11.9% | |
| Q3 2017 | +25.8% | +44.7% | +75.2% | |
| Q2 2017 | -4.2% | -0.1% | -2.4% | |
| Q1 2017 | +12.5% | +11.5% | +28.0% | |
| Q4 2016 | +7.9% | +7.4% | -34.6% | |
| Q3 2016 | +7.9% | +1.8% | -0.1% | |
| Q2 2016 | -13.1% | -9.7% | -23.8% | |
| Q1 2016 | -3.0% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | -10.4% | — | — | |
| Q2 2015 | -4.3% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q1 2014 | -0.8% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro